Ask AI
ProCE Banner Activity

IMPALA: Long-acting Cabotegravir + Rilpivirine in Adults With Poorly Controlled HIV Infection in Sub-Saharan Africa

Conference Coverage
Slideset

Long-acting cabotegravir plus rilpivirine given every 2 months was noninferior to dolutegravir-based ART in an African cohort with prior suboptimal HIV control.

Released: July 18, 2025

Expiration: January 17, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner